BenoBio
- Biotech or pharma, therapeutic R&D
Beno Bio is a South Korean biotech company founded in 2018. The company develops innovative therapies based on epigenetic regulation aiming to treat inflammatory diseases, age-related conditions, and cancer.
Beno Bio’s approach focuses on modulating gene expression without altering DNA sequences. Its lead pipeline, BBRP11001, targets wet age-related macular degeneration (wet AMD),with additional programs in Pan Kras, Osteoarthritis and IBD.
The company has completed key preclinical studies for its wet AMD program and entered Phase 1 clinical development.
Beno Bio is actively seeking global partners for co-development and licensing opportunities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}